Results 91 to 100 of about 18,118,892 (286)

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold

Health Technology Assessment, 2015
Background: Cost-effectiveness analysis involves the comparison of the incremental cost-effectiveness ratio of a new technology, which is more costly than existing alternatives, with the cost-effectiveness threshold.
Karl Claxton, Steve Martin, Marta Soares, Nigel Rice, Eldon Spackman, Sebastian Hinde, Nancy Devlin, Peter C Smith, Mark Sculpher   +8 more
doaj   +1 more source

Willingness to pay per quality-adjusted life year per gross domestic product per capita by country.

Willingness to pay per quality-adjusted life year per gross domestic product per capita by country.
Klas Göran Sahlen (17935584), Lars Lindholm (21685), Anh Nu Vu (17935581), Minh Van Hoang (6842081), Cuc Thi Thu Nguyen (14059662), Sun Sun (15469762)   +5 more
core   +1 more source

Justifying Terminal Care by 'Retrospective Quality-Adjusted Life-Years'

, 2010
A lot of medical procedures can be justified in terms of the number of quality-adjusted life-years (QALYs) they can be expected to generate; that is, the number of extra years that the procedure will provide, with the quality of life during those extra ...
Cowley, Christopher
core   +1 more source

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

Molecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic, Rafael Stroggilos, Mladen Marinkovic, Ana Djuric, Suzana Stojanovic‐Rundic, Radmila Jankovic, Sergi Castellvi‐Bel, Remond J.A. Fijneman, Antonia Vlahou, Jerome Zoidakis, Milena Cavic   +10 more
wiley   +1 more source

Global economic differences in modern glioblastoma care – a systematic review

Acta Neurochirurgica
Purpose Glioblastoma (GBM) is the most aggressive form of primary brain cancer and is associated with poor overall survival and expensive, resource intensive treatments.
Reuben Christopher, Livia Stauner, Mathias Spendel, Arwin Rezai, Alexander Romagna, Christoph Schwartz   +5 more
doaj   +1 more source

Assessment of cost-effectiveness threshold using a double-bounded dichotomous choice model

Public Health in Practice
Objectives: Willingness to pay (WTP) for one quality-adjusted life year (QALY) is highly variable according to survey methodology and can change over time, even within the same population.
Taito Kitano, Shinya Tsuzuki
doaj   +1 more source

Peer effects in health valuation: the relation between rating of contemporaries’ health and own health

Health and Quality of Life Outcomes, 2018
Background Most health valuation studies assume that individuals’ health valuations do not depend on social comparisons. However, there is some evidence that this assumption is not satisfied in practice.
Arthur E. Attema, Werner B. F. Brouwer, Jose Luis Pinto Prades   +2 more
doaj   +1 more source

Lifetime societal costs and quality-adjusted life years.

, 2023
Lifetime societal costs and quality-adjusted life years.
Marianne Hamilton Lopez (15314696), Joanne Kurtzberg (832027), Evan Myers (353856), Beth Shaz (15314699), Ethan D. Borre (6890177), Jesse Troy (15314702), Gillian D. Sanders Schmidler (15314705)   +6 more
core   +1 more source

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

Molecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth, Rui P. L. Neves, Julia Geheb, Christian Ballmeyer, Nathalie Gaßmann, Kiki C. Andree, Monica Sudarsanam, Christiane Driemel, Celine Örencik, Andrè Franken, Eslam Elmaghraby, Sven H. Loosen, Roderburg Christoph, Sebastian Schoelch, Hans Neubauer, Wolfram T. Knoefel, Nikolas H. Stoecklein, Georg Fluegen   +17 more
wiley   +1 more source